Publications Office of the EU
Acquisition of Talketamab (Talvey) - EU tenders
DisplayCustomHeader
MyPortal
Language Selector
English
BasketSummary
Procurement Detail Actions Portlet

Utilities

Procurement Detail Actions Portlet
OP Portal - Procurement - Details

This page contains content generated automatically to improve findability and accessibility

- indicates text translated automatically in your browsing language

Acquisition of Talketamab (Talvey) Text automatically translated in your browsing language Automatically translated

Overview
  • Awarded
    05/12/2024
  • Today
    16/01/2025
Status
Awarded
Type of contract
Supplies
Subject for Renewal
No
Buyer
HUS Group, the joint authority for Helsinki and Uusimaa
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: FI1B1 Helsinki-Uusimaa
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
520,000.00 EUR
Procedure details
Tender reference number
Not available
Description

Acquisition of Talketamab (Talvey solution for injection) to ensure continued treatment as monotherapy for the treatment of relapsed and refractory multiple myeloma in adult patients who have received at least three prior treatments, including an immunomodulatory agent, a proteasome inhibitor and an antibody to CD38, and whose disease has been shown to have progressed during the most recent treatment. Talketamab is a double-specific IgG4-PAA (immunoglobulin G4 proline, alanine, alanine) antibody that targets the GPRC5D receptor and the CD3 receptor on the surface of T cells. T cells are activated, causing the death of GPRC5D cells. Talketamab has been used in HUS. Patients have achieved deep and long-lasting responses to treatment and are refractories to other myeloma medicines. Text automatically translated in your browsing language Automatically translated

Submission Method
Not available
Tenders may be submitted
Not available
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
Not available
Conditions for opening tenders (date)
Not available
Place of performance
FI1B1 Helsinki-Uusimaa
FI Suomi/Finland
CPV code

33600000 - Pharmaceutical products

Award method
Criterion:
Type: cost
Description: Arvioidun kokonaiskulutuksen yhteenlasketut kustannukset. Suomen markkinoilla on vain yksi myyntiluvallinen talketamabivalmiste.
Weight (percentage, exact):
Estimated value
Not available
Final contracted value
520,000.00 EUR
Award of contract
Official name: Janssen-Cilag Oy
Postal address:
Town: Espoo
Postal code: 02621
Country:
Documents
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.